Citations

Clear

626 citation(s) found for "Mehta, SH".

Response to Letter Regarding Article “Impact of Annual Operator and Institutional Volume on Percutaneous Coronary Intervention Outcomes: A 5-Year United States Experience (2005–2009)”
Badheka, Apurva O., Patel, Nileshkumar, Grover, Peeyush , Singh, Vikas , Patel, Nilay , Arora, Shilpkumar , Chothani, Ankit , Mehta, Kathan , Deshmukh, Abhishek , Savani, Ghanshyambhai T., Patel, Achint , Panaich, Sidakpal , Shah, Neeraj , Brown, Michael, Mohamad, Tamam , Makkar, Raj , Schreiber, Theodore , Rihal, Charanjit S. , Cohen, Mauricio G. , Rathod, Ankit D. , Grines, Cindy L. , Rihal, Charanjit S. , Panaich, Sidakpal S , Cohen, Mauricio G

Mayo Clinic

Circulation | August 3, 2015 | Volume: 132 | Issue: 5 | Pages: No page available

10.1161/circulationaha.115.015221 | PMID 26240270 Get It

Defining the Eye-of-the-Tiger Sign
Mehta, Shyamal H. , Morgan, John C. , Sethi, Kapil D.

Mayo Clinic

JAMA Neurology | May 11, 2015 | Volume: 72 | Issue: 5 | Pages: 606

10.1001/jamaneurol.2015.0144 | PMID 25961178 Get It

Transition to turbulence in acoustically driven flows
Thompson, Charles , Chandra, Kavitha , Denis, Max , Mehta, Vineet

Mayo Clinic

Journal of the Acoustical Society of America | May 1, 2015 | Volume: 137 | Issue: 4_Supplement | Pages: 2223-2223

10.1121/1.4920098 Get It

Direct numerical solutions of the three-dimensional time-dependent Navier-Stokes equation are presented for the evolution of three-dimensional finite-amplitude disturbances in the Stokes boundary layer. The basic flow is driven harmonically in time and the disturbances represent a departure from the basic state of the fluid. For fixed value of the fluid viscosity, instability is shown to be a function of the amplitude of oscillation of the basic flow, excitation frequency, and the channel wall geometry. Special attention is given to pressure gradient and surface wave driven flows. Conditions for instability and transition are outlined.
Influence of hospital volume on outcomes of percutaneous atrial septal defect and patent foramen ovale closure: A 10‐years us perspective
Singh, Vikas , Badheka, Apurva O., Patel, Nileshkumar, Chothani, Ankit , Mehta, Kathan , Arora, Shilpkumar , Patel, Nilay , Deshmukh, Abhishek , Shah, Neeraj , Savani, Ghanshyambhai T., Manvar, Sohilkumar, Thakkar, Badal, Panchal, Vinaykumar , Palacios, Igor F. , Rihal, Charanjit S. , Cohen, Mauricio G. , Marchena, Eduardo de , Rathod, Ankit D. , Patel, Jay N. , Rihal, Charanjit S. , O’Neill, William W. , Cohen, Mauricio G

Mayo Clinic

Catheterization and Cardiovascular Interventions | December 22, 2014 | Volume: 85 | Issue: 6 | Pages: 1073-1081

10.1002/ccd.25794 | PMID 25534392 Get It

Background: Contemporary data regarding percutaneous closure of atrial septal defect/patent foramen ovale (ASD/PFO) are lacking. We evaluated the current trends in utilization of ASD/PFO closure in adults and investigated the effect of annual hospital volume on in‐hospital outcomes. Methods: We queried the Nationwide Inpatient Sample between the years 2001 and 2010 using the International Classification of Diseases (ICD‐9‐CM) procedure code for percutaneous closure of ASD/PFO with device. Hierarchical mixed effects models were generated to identify the independent multivariate predictors of outcomes. Results: A total of 7,107 percutaneous ASD/PFO closure procedures (weighted n = 34,992) were available for analysis. A 4.7‐fold increase in the utilization of this procedure from 3/million in 2001 to 14/million adults in 2010 in US (P < 0.001) was noted. Overall, percutaneous ASD/PFO closure was associated with 0.5% mortality and 12% in‐hospital complications. The utilization of intracardiac echocardiography (ICE) increased 15 fold (P < 0.001) during the study period. The procedures performed at the high volume hospitals [2nd (14–37 procedures/year) and 3rd (>38 procedures/year) tertile] were associated with significant reduction in complications, length of stay and cost of hospitalization when compared to those performed at lowest volume centers (<13 procedures/year). Majority (70.5%) of the studied hospitals were found to be performing <10 procedures/year hence deviating from the ACC/AHA/SCAI clinical competency guidelines. Conclusions: Low hospital volume is associated with an increased composite (mortality and procedural complications) adverse outcome following ASD/PFO closure. In the interest of patient safety, implementation of the current guidelines for minimum required annual hospital volume to improve clinical outcomes is warranted. © 2014 Wiley Periodicals, Inc.
miR30a Inhibits LOX Expression and Anaplastic Thyroid Cancer Progression
Boufraqech, Myriem , Nilubol, Naris , Gara, Sudheer Kumar, Sadowski, Samira M. , Mehta, Amit, Davis, Sean , Dreiling, Jennifer L., Copland, John A. , Smallridge, Robert C., Quezado, Martha , Kebebew, Electron , Zhang, Lisa M. , He, Mei

Mayo Clinic

Cancer Research | December 9, 2014 | Volume: 75 | Issue: 2 | Pages: 367-377

10.1158/0008-5472.can-14-2304 | PMID 25488748 Get It

Abstract Anaplastic thyroid cancer (ATC) is one of the most lethal human malignancies, but its genetic drivers remain little understood. In this study, we report losses in expression of the miRNA miR30a, which is downregulated in ATC compared with differentiated thyroid cancer and normal tissue. miR30a downregulation was associated with advanced differentiated thyroid cancer and higher mortality. Mechanistically, we found miR30a decreased cellular invasion and migration, epithelial–mesenchymal transition marker levels, lysyl oxidase (LOX) expression, and metastatic capacity. LOX was identified as a direct target of miR30a that was overexpressed in ATC and associated with advanced differentiated thyroid cancer and higher mortality rate. Consistent with its role in other cancers, we found that LOX inhibited cell proliferation, cellular invasion, and migration and metastasis in vitro and in vivo. Together, our findings establish a critical functional role for miR30a downregulation in mediating LOX upregulation and thyroid cancer progression, with implications for LOX targeting as a rational therapeutic strategy in ATC. Cancer Res; 75(2); 367–77. ©2014 AACR.
Abstract A110: EGFRvIII expression is associated with shorter progression-free and overall survival in glioblastoma patients treated with standard-of-care temozolomide and radiation: A report from the RTOG-0525 trial.
George, Asha , Chakravarti, Arnab , Brown, Paul D. , Jaeckle, Kurt A. , Corn, Benjamin W. , Sulman, Erik P. , Souhami, Luís, Werner‐Wasik, Maria, Anderson, Bethany , Aldape, Kenneth , Cahill, Daniel P. , Gilbert, Mark R. , Stupp, Roger , Hegi, Monika E. , Mehta, Minesh P. , Sulman, Erik P

Mayo Clinic

Molecular Cancer Therapeutics | August 14, 2014 | Volume: 12 | Issue: 11_Supplement | Pages: A110-A110

10.1158/1535-7163.targ-13-a110 Get It

Abstract Background: Glioblastomas (GBMs) are aggressive primary brain tumors with high levels of genomic heterogeneity impacting prognosis and treatment response. A recurrent in-frame deletion within the extracellular domain of the epidermal growth factor receptor (EGFR variant III, or vIII) is found in a substantial fraction of GBMs. Methods: The Radiation Therapy Oncology Group (RTOG) 0525 trial of temozolomide dosing in newly-diagnosed GBM enrolled 1174 patients. Of these, 494 eligible GBMs were analyzed for EGFRvIII expression by RT-PCR. The Kaplan-Meier method was used to compare the progression free survival (PFS) and overall survival (OS) of GBMs expressing EGFRvIII with those not expressing EGFRvIII. Results: 142 of 494 tested GBMs (29%) had expressed EGFRvIII. There were no significant differences in PFS or OS between patients whose tumors did (494) or did not (631) undergo EGFRvIII expression analysis. EGFRvIII expression was significantly associated with age (p=0.005), Karnofsky performance status (p=0.02), and RTOG recursive partitioning analysis (RPA) class (p=0.005). EGFRvIII expression analyzed in the entire study population did not reveal an association with PFS or OS. In a univariate subgroup analysis of patients treated on the standard-of-care arm of RTOG-0525, EGFRvIII expression was was significantly associated with worse PFS (HR=1.43, 95% CI: [1.05, 1.96], p=0.025), and worse OS (HR 1.45, 95% CI:[1.03, 2.05], p=0.032). However, in multivariate models, when adjusted for RPA class and MGMT methylation status, EGFRvIII was not an independent predictor of either PFS or OS. Conclusion: For GBMs treated with standard-of-care therapy in RTOG-0525, EGFRvIII expression was associated with worse PFS and OS. However, well-established stratification metrics such as age, KPS, and RPA override this prognostic association, suggesting that trials of therapeutic modalities directed against EGFRvIII should utilize these standard prognostic variables when survival is being analyzed or compared. Project Support: This project was supported by RTOG grant U10 CA21661, and CCOP grant U10 CA37422 from the National Cancer Institute (NCI) and Schering-Plough Corporation. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):A110. Citation Format: Daniel P. Cahill, Asha George, Mark R. Gilbert, Arnab Chakravarti, Roger Stupp, Monika Hegi, Paul Brown, Kurt A. Jaeckle, Benjamin Corn, Erik P. Sulman, Luis Souhami, Maria Werner-Wasik, Bethany M. Anderson, Minesh Mehta, Kenneth D. Aldape. EGFRvIII expression is associated with shorter progression-free and overall survival in glioblastoma patients treated with standard-of-care temozolomide and radiation: A report from the RTOG-0525 trial. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr A110.
Extended Antimicrobial Use in Patients Undergoing Percutaneous Nephrolithotomy and Associated Antibiotic Related Complications
Viers, Boyd R. , Cockerill, Patrick, Mehta, Ramila A. , Bergstralh, Eric J., Krambeck, Amy E. , Cockerill, Patrick A, Viers, Boyd R

Mayo Clinic

Journal of Urology | July 3, 2014 | Volume: 192 | Issue: 6 | Pages: 1667-1672

10.1016/j.juro.2014.06.090 | PMID 24998482 Get It

High-Sensitivity Troponin I and Amino-Terminal Pro–B-Type Natriuretic Peptide Predict Heart Failure and Mortality in the General Population
AbouEzzeddine, Omar F. , Mehta, Ramila A. , Rodeheffer, Richard J. , Redfield, Margaret M. , Burnett, John C. , Jaffe, Allan S. , McKie, Paul M. , Scott, Christopher G. , Jaffe, Allan S. , AbouEzzeddine, Omar F

Mayo Clinic

Clinical Chemistry | July 2, 2014 | Volume: 60 | Issue: 9 | Pages: 1225-1233

10.1373/clinchem.2014.222778 | PMID 24987112 Get It

Abstract INTRODUCTION High-sensitivity cardiac troponin assays have potent prognostic value in stable cardiovascular disease cohorts. Our objective was to assess the prognostic utility of a novel cardiac troponin I (cTnI) high-sensitivity assay, independently and in combination with amino-terminal pro–B-type natriuretic peptide (NT-proBNP), for the future development of heart failure and mortality in the general community. METHODS A well-characterized community-based cohort of 2042 participants underwent clinical assessment and echocardiographic evaluation. Baseline measurements of cTnI with a high-sensitivity assay and NT-proBNP were obtained in 1843 individuals. Participants were followed for new-onset heart failure and mortality with median (25th, 75th percentile) follow-up of 10.7 (7.9, 11.6) and 12.1 (10.4, 13.0) years, respectively. RESULTS When measured with a high-sensitivity assay, cTnI greater than the sex-specific 80th percentile was independently predictive of heart failure [hazard ratio 2.56 (95% confidence interval 1.88–3.50), P &lt; 0.001] and mortality [1.91(1.49–2.46), P &lt; 0.001] beyond conventional risk factors in this community-based cohort, with significant increases in the net reclassification improvement for heart failure. The prognostic utility of cTnI measured with a high-sensitivity assay goes beyond NT-proBNP, yet our data suggest that these 2 assays are complementary and most beneficial when evaluated together in identifying at-risk individuals in the community. CONCLUSIONS Our findings lay the foundation for prospective studies aimed at identification of individuals at high risk by use of a multimarker approach, followed by aggressive prevention strategies to prevent subsequent heart failure.
Effectiveness of Anti-TNFα for Crohn Disease: Research in a Pediatric Learning Health System
Crandall, Wallace, Joffe, Marshall M., Colletti, Richard B. , Adler, Jeremy, Baron, Howard, Berman, James , Rosario, J. Fernando del , Grossman, Andrew B., Israel, Esther J. , Kim, Sandra C. , Lightdale, Jenifer R. , Margolis, Peter A. , Marsolo, Keith , Mehta, Devendra I. , Milov, David E., Patel, Ashish , Tung, Jeanne , Forrest, Christopher B. , Bailey, L. Charles , Zhang, Peixin , Adler, Jeremy, Hoffenberg, Edward J. , Kappelman, Michael D. , Adler, J

Mayo Clinic

Pediatrics | June 17, 2014 | Volume: 134 | Issue: 1 | Pages: 37-44

10.1542/peds.2013-4103 | PMID 24935993 Get It

OBJECTIVES: ImproveCareNow (ICN) is the largest pediatric learning health system in the nation and started as a quality improvement collaborative. To test the feasibility and validity of using ICN data for clinical research, we evaluated the effectiveness of anti-tumor necrosis factor-α (anti-TNFα) agents in the management of pediatric Crohn disease (CD). METHODS: Data were collected in 35 pediatric gastroenterology practices (April 2007 to March 2012) and analyzed as a sequence of nonrandomized trials. Patients who had moderate to severe CD were classified as initiators or non-initiators of anti-TNFα therapy. Among 4130 patients who had pediatric CD, 603 were new users and 1211 were receiving anti-TNFα therapy on entry into ICN. RESULTS: During a 26-week follow-up period, rate ratios obtained from Cox proportional hazards models, adjusting for patient and disease characteristics and concurrent medications, were 1.53 (95% confidence interval [CI], 1.20–1.96) for clinical remission and 1.74 (95% CI, 1.33–2.29) for corticosteroid-free remission. The rate ratio for corticosteroid-free remission was comparable to the estimate produced by the adult SONIC study, which was a randomized controlled trial on the efficacy of anti-TNFα therapy. The number needed to treat was 5.2 (95% CI, 3.4–11.1) for clinical remission and 5.0 (95% CI, 3.4–10.0) for corticosteroid-free remission. CONCLUSIONS: In routine pediatric gastroenterology practice settings, anti-TNFα therapy was effective at achieving clinical and corticosteroid-free remission for patients who had Crohn disease. Using data from the ICN learning health system for the purpose of observational research is feasible and produces valuable new knowledge.